CDSCO panel approves Oxford COVID-19 vaccine for emergency use
Team Udayavani, Jan 1, 2021, 5:47 PM IST
New Delhi: An expert panel on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) has approved the emergency use authorisation for the Oxford COVID-19 vaccine Covishield, being manufactured by Serum Institute of India.
The Pune-based Serum Institute of India (SII), the world’s largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Wednesday had approved the COVID-19 vaccine developed by scientists at Oxford University and produced by AstraZeneca for human use.
The Subject Expert Committee (SEC) on COVID-19 of the CDSCO, which had earlier sought additional safety and immunogenicity data from SII, deliberated on its application seeking emergency use authorisation (EUA) for the shots on Wednesday, and met again on Friday to review the matter.
More details to be added
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
INX Media case: Delhi court allows Congress MP Karti Chidambaram to travel abroad
Parcel blast case: Accused learned to make bombs on internet to target in-laws; arrested with aide
Persecution in the name of Dharma took place due to lack of its understanding: Bhagwat
Will SC conduct further inquiry, asks Surjewala after Pegasus spyware case verdict in US
Rahul summoned by Bareilly court for remarks against Economic Survey
MUST WATCH
Latest Additions
INX Media case: Delhi court allows Congress MP Karti Chidambaram to travel abroad
Take steps to establish NIMHANS and diabetology units in Kalaburagi and Mysuru: CM Siddaramaiah
PM Modi receives Kuwait’s highest honour
Parcel blast case: Accused learned to make bombs on internet to target in-laws; arrested with aide
RBI: After another status quo year, all eyes on a growth-propping rate cut with new Guv at helm
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.